Skip to main content
eScholarship
Open Access Publications from the University of California

A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model

  • Author(s): Lin, Y
  • Luo, J
  • Zhu, WE
  • Srivastava, M
  • Schaue, D
  • Elashoff, DA
  • Dubinett, SM
  • Sharma, S
  • Wu, B
  • St. John, MA
  • et al.

Published Web Location

http://oto.sagepub.com/content/151/3/447.long
No data is associated with this publication.
Abstract

Objective. This study aimed to evaluate the therapeutic efficacy of a novel polymer platform delivering cisplatin and cytokines in the treatment of head and neck squamous cell carcinoma (HNSCC). Study Design. In vivo study. Setting. Academic research laboratory. Subjects and Methods. Mice were randomized to receive implantation of (1) no polymer, (2) plain polymer, (3) plain polymer with local cisplatin injection, or (4) cisplatin polymer. The 2 groups of mice implanted with cisplatin polymer or no polymer were further randomized to receive (1) 4 Grays external beam radiation for 4 days or (2) no radiation. For cytokine studies, mice were grouped into (1) no polymer, (2) plain polymer, (3) plain polymer with intratumoral injection of recombinant CCL21 twice a week, (4) polymer containing parental dendritic cells, or (5) polymer containing dendritic cells secreting CCL21 (DC-CCL21). Results. The cisplatin-secreting polymer effectively reduced tumors in the mice by more than 16-fold (P <.01). We also observed a statistically significant lower tumor weight among mice treated with cisplatin polymer and concomitant radiation compared to control groups. The DC-CCL21 polymer reduced SCCVII/SF tumors in the C3H/HeJ mice by more than 41% (P<.01). Conclusion. Herein, we demonstrate the efficacy of a novel polymer platform in delivering cisplatin and cytokines. We also demonstrate that we can effectively grow dendritic cells in the polymer that can actively secrete CCL21 for a minimum of 5 days. This polymer may represent a new therapeutic modality for patients with HNSCC. Once this polymer platform is optimized, we will plan to pursue prospective trials in patients with HNSCC. © American Academy of Otolaryngology-Head and Neck Surgery Foundation 2014.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item